Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus CLARITIN D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus CLARITIN D 24 HOUR.
CLARITIN REDITABS vs CLARITIN-D 24 HOUR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
Seasonal allergic rhinitisPerennial allergic rhinitisIdiopathic chronic urticaria
Relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, rhinorrhea, nasal congestion, pruritus)Relief of nasal congestion associated with the common cold
10 mg orally once daily.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Extensively metabolized in the liver via CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine; undergoes first-pass metabolism.
Loratadine: extensively metabolized by CYP3A4 and CYP2D6 to active metabolite desloratadine; pseudoephedrine: partially metabolized in liver by N-demethylation.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Loratadine: 97% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
Loratadine: 97-99% bound to plasma proteins (mainly albumin and α1-acid glycoprotein); desloratadine: 73-76% bound.
Loratadine: 4.5 L/kg. Desloratadine: 90 L/kg. High Vd indicates extensive tissue distribution.
Loratadine: 119 L/kg (apparent Vd/F ~1000 L). High Vd indicates extensive tissue distribution. Desloratadine: 148 L/kg (apparent Vd/F ~2500 L).
Orally disintegrating tablet: Bioequivalent to conventional tablets; absolute bioavailability ~100% (extensive first-pass metabolism: 3% parent drug reaches systemic circulation, but active metabolite contributes to effect).
Oral: Loratadine absolute bioavailability is ~40% due to first-pass metabolism; food increases AUC by 40% and delays Tmax. Desloratadine absolute bioavailability is ~50%.
For GFR <10 mL/min: 10 mg orally every other day. No adjustment needed for GFR ≥10 mL/min.
GFR 30-89 mL/min: no adjustment; GFR <30 mL/min or ESRD: contraindicated due to pseudoephedrine component
Child-Pugh A: no adjustment. Child-Pugh B or C: 10 mg orally every other day.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: contraindicated due to insufficient data
6 years and older: 10 mg orally once daily. 2-5 years: 5 mg orally once daily (if using oral solution). REDITABS not recommended under 6 years.
Not recommended for children under 12 years; age 12-17 years: 1 tablet orally once daily
Adjust dosing based on renal function; more sensitive to anticholinergic effects; caution in patients over 65 with renal impairment.
Caution in patients >60 years due to increased sensitivity to pseudoephedrine (nervousness, dizziness, sleep disturbances) and higher risk of adverse effects; consider alternative therapy
None
None.
["Caution in hepatic impairment; dose adjustment recommended","Caution in severe renal impairment (CrCl <30 mL/min)","May cause drowsiness; avoid driving if affected"]
["Cardiovascular effects: caution in hypertension, arrhythmias, ischemic heart disease","Central nervous system stimulation: may cause insomnia, dizziness, tremor","Urinary retention: caution in patients with prostatic hypertrophy","Glaucoma: may increase intraocular pressure","Use with MAOIs: hypertensive crisis risk","Diabetes: may increase blood glucose"]
["Hypersensitivity to loratadine or any component","Lactation (use with caution)"]
["Hypersensitivity to loratadine, pseudoephedrine, or any component","Severe hypertension","Severe coronary artery disease","Concurrent use or within 14 days of MAOIs","Narrow-angle glaucoma","Urinary retention","Lactation (due to pseudoephedrine)"]
Data Pending Review
Data Pending Review
No significant food interactions reported. Avoid concomitant use with alcohol as it may increase risk of drowsiness. Grapefruit juice does not significantly affect loratadine metabolism.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) due to potential hypertensive crisis with pseudoephedrine. Grapefruit juice may increase pseudoephedrine absorption; limit intake. Avoid alcohol, which can exacerbate CNS sedation from loratadine.
Loratadine (Claritin Reditabs) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. First trimester: In a large prospective study with 681 pregnant women exposed to loratadine, no increased risk of major congenital malformations was observed compared to unexposed controls. Second and third trimesters: Limited data, but no evidence of fetotoxicity or adverse neonatal outcomes. Overall, the risk is considered low, but use only if clearly needed.
FDA Pregnancy Category B. Animal studies show no fetal risk; no adequate human studies in first trimester. Pseudoephedrine may cause uterine vasoconstriction; avoid in preeclampsia or reduced placental perfusion. No known teratogenicity from loratadine or pseudoephedrine in human pregnancy.
Loratadine is excreted into human breast milk. The calculated milk/plasma (M/P) ratio for loratadine and its active metabolite descarboethoxyloratadine is approximately 1.2 and 0.9, respectively. The relative infant dose (RID) is estimated to be 0.4-1.1% of the maternal weight-adjusted dose, which is low and unlikely to cause adverse effects in infants. However, due to long half-life (12-15 hours), use caution; a shorter-acting antihistamine may be preferred for breastfeeding women.
Loratadine: M/P ratio ~1.2; excreted in breast milk in low amounts (0.029% of maternal dose). Pseudoephedrine: M/P ratio ~3.5; excreted in milk (4-6% of maternal dose), may reduce milk production and cause irritability in infants. Use caution, especially with high doses or prolonged use.
No pharmacokinetic studies specifically in pregnant women have shown significant changes in loratadine absorption, distribution, metabolism, or excretion that require dose adjustment. However, physiological changes in pregnancy (e.g., increased volume of distribution, enhanced renal clearance) may theoretically alter drug levels, but clinical data do not support need for dose modification. Standard adult dosing (10 mg once daily) is appropriate if used.
No dose adjustment typically required; pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not significant enough to require dose modification. Use lowest effective dose, avoid in severe hypertension or coronary artery disease.
Category C
Category C
Claritin Reditabs (loratadine) are orally disintegrating tablets that rapidly dissolve on the tongue, making them ideal for patients with swallowing difficulties. Onset of action occurs within 1-3 hours, with peak effect at 8-12 hours. Avoid use in severe hepatic impairment; consider dose adjustment for hepatic or renal impairment.
CLARITIN-D 24 HOUR combines loratadine (antihistamine) and pseudoephedrine (decongestant). Avoid in patients with severe hypertension, coronary artery disease, or MAOI use within 14 days. Monitor for insomnia, tachycardia, and urinary retention, especially in elderly males with BPH. Contraindicated in narrow-angle glaucoma.
Place the tablet on the tongue; it will dissolve rapidly without water.Do not chew or swallow the tablet whole.Use as directed for allergy symptoms; do not exceed 1 tablet per day.May cause drowsiness in some patients; avoid driving until you know how you react.Store in a dry place; do not remove from blister pack until ready to use.
Do not crush or chew the tablet; swallow whole with a full glass of water.Avoid taking within 4-6 hours of bedtime to prevent insomnia.Do not use with other decongestants or cold remedies containing pseudoephedrine.Discontinue and consult healthcare provider if you experience chest pain, rapid heart rate, dizziness, or difficulty urinating.